Read
- Survivors pulled from Oklahoma tornado debris as toll lowered
|
- Convicted U.S. killer Arias would join tiny death row group
- Drop in U.S. underground water levels has accelerated -USGS
- Israel fires back at Syria after gunshots at its troops
- Analysis: Some Republicans see new scandal in Sebelius fundraising
Reuters Photojournalism
Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography. See more | Photo caption
Devastated by tornado
A huge tornado tears through the Oklahoma City suburb of Moore, killing dozens. Slideshow
Sponsored Links
Pfizer kidney cancer drug gets EU approval
People walk past the Pfizer World headquarters in New York, February 3, 2010.
Credit: Reuters/Brendan McDermid
(Reuters) - Pfizer Inc said its oral drug Inlyta received European approval as a second-line treatment for kidney cancer patients who do not respond to an initial chemotherapy.
The company said the approval was based on data from a late-stage trial which showed that the drug significantly extended progression-free survival in patients who failed to respond to treatment with Pfizer's Sutent.
Inlyta was approved in the United States for the same indication in January.
The drug, generically known as axitinib, works by inhibiting proteins that can influence tumor growth and cancer progression.
Renal cell carcinoma affects 102,000 people in Europe every year, the company said in a statement.
Pfizer's shares closed at $23.86 on the New York Stock Exchange on Friday.
(Reporting By Vrinda Manocha in Bangalore; Editing by Anthony Kurian)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters